Association of 10-Year C-Reactive Protein Trajectories With Markers of Healthy Aging: Findings From the English Longitudinal Study of Aging.
Activities of Daily Living
Aged
Aged, 80 and over
Aging
/ physiology
Biomarkers
/ blood
C-Reactive Protein
/ metabolism
Cross-Sectional Studies
England
/ epidemiology
Female
Follow-Up Studies
Humans
Incidence
Inflammation
/ blood
Male
Middle Aged
Odds Ratio
Prospective Studies
Walking Speed
/ physiology
Journal
The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837
Informations de publication
Date de publication:
16 01 2019
16 01 2019
Historique:
received:
16
08
2017
pubmed:
21
2
2018
medline:
2
11
2019
entrez:
21
2
2018
Statut:
ppublish
Résumé
Elevated systematic inflammation is a hallmark of aging, but the association of long-term inflammation trajectories with subsequent aging phenotypes has been little examined. We assessed inflammatory marker C-reactive protein (CRP) repeatedly over time and examined whether long-term changes predicted aging outcomes. A total of 2,437 men and women aged 47-87 years at baseline (1998-2001) who were participants in the English Longitudinal Study of Ageing had CRP measured on two or three occasions between 1998 and 2009. Inflammation trajectories were computed using latent-class growth mixture modeling and were related to aging outcomes measured in 2012/2013: physical functioning, cardiometabolic, respiratory, mental health, and a composite "healthy aging" outcome. Four CRP trajectories were identified as follows: "stable-low" (71 per cent of the sample) with baseline mean 1.33 mg/L remaining <3 mg/L; "medium-to-high" (14 per cent) with baseline 2.7 mg/L rising to 5.3 mg/L; "high-to-medium" (10 per cent) with baseline 6.6 mg/L decreasing to 2.4 mg/L; and "stable-high" (5 per cent) with levels from 5.7 to 7.5 mg/L. Relative to the stable-low trajectory, individuals in the medium-to-high had a higher risk of limitations in basic activities of daily living (ADL, odds ratio; 95% confidence interval: 2.09; 1.51, 2.88), instrumental ADL (1.62; 1.15, 2.30), impaired balance (1.59; 1.20, 2.11) and walking speed (1.61; 1.15, 2.24), arthritis (1.55; 1.16, 2.06), hypertension (1.57; 1.21, 2.04), obesity (1.95; 1.36, 2.80), poor respiratory function (1.84; 1.36, 2.50), and depression (1.55; 1.13, 2.12). A lower odds of healthy aging was observed in people in the medium-to-high (0.57; 0.40, 0.79) and stable-high (0.50; 0.27, 0.91) trajectories. Older people who displayed an elevation in CRP levels over a decade experienced an increased risk of adverse aging outcomes.
Sections du résumé
Background
Elevated systematic inflammation is a hallmark of aging, but the association of long-term inflammation trajectories with subsequent aging phenotypes has been little examined. We assessed inflammatory marker C-reactive protein (CRP) repeatedly over time and examined whether long-term changes predicted aging outcomes.
Methods
A total of 2,437 men and women aged 47-87 years at baseline (1998-2001) who were participants in the English Longitudinal Study of Ageing had CRP measured on two or three occasions between 1998 and 2009. Inflammation trajectories were computed using latent-class growth mixture modeling and were related to aging outcomes measured in 2012/2013: physical functioning, cardiometabolic, respiratory, mental health, and a composite "healthy aging" outcome.
Results
Four CRP trajectories were identified as follows: "stable-low" (71 per cent of the sample) with baseline mean 1.33 mg/L remaining <3 mg/L; "medium-to-high" (14 per cent) with baseline 2.7 mg/L rising to 5.3 mg/L; "high-to-medium" (10 per cent) with baseline 6.6 mg/L decreasing to 2.4 mg/L; and "stable-high" (5 per cent) with levels from 5.7 to 7.5 mg/L. Relative to the stable-low trajectory, individuals in the medium-to-high had a higher risk of limitations in basic activities of daily living (ADL, odds ratio; 95% confidence interval: 2.09; 1.51, 2.88), instrumental ADL (1.62; 1.15, 2.30), impaired balance (1.59; 1.20, 2.11) and walking speed (1.61; 1.15, 2.24), arthritis (1.55; 1.16, 2.06), hypertension (1.57; 1.21, 2.04), obesity (1.95; 1.36, 2.80), poor respiratory function (1.84; 1.36, 2.50), and depression (1.55; 1.13, 2.12). A lower odds of healthy aging was observed in people in the medium-to-high (0.57; 0.40, 0.79) and stable-high (0.50; 0.27, 0.91) trajectories.
Conclusions
Older people who displayed an elevation in CRP levels over a decade experienced an increased risk of adverse aging outcomes.
Identifiants
pubmed: 29462285
pii: 4859593
doi: 10.1093/gerona/gly028
pmc: PMC6333942
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
195-203Subventions
Organisme : Medical Research Council
ID : K013351
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K013351/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG017644
Pays : United States
Références
Int J Epidemiol. 2013 Dec;42(6):1640-8
pubmed: 23143611
Ageing Res Rev. 2011 Jul;10(3):319-29
pubmed: 21145432
J Am Med Dir Assoc. 2013 Dec;14(12):877-82
pubmed: 23792036
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73
pubmed: 24222018
Am J Med. 2006 Jun;119(6):526.e9-17
pubmed: 16750969
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1327-9
pubmed: 22174110
Mech Ageing Dev. 2007 Jan;128(1):92-105
pubmed: 17116321
Circulation. 2003 Jan 28;107(3):499-511
pubmed: 12551878
N Engl J Med. 2005 Apr 21;352(16):1685-95
pubmed: 15843671
CMAJ. 2013 Nov 5;185(16):E763-70
pubmed: 24043651
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Age Ageing. 2012 Jul;41(4):541-5
pubmed: 22417984
Science. 1996 Jul 5;273(5271):70-4
pubmed: 8658199
BMJ. 2011 Feb 15;342:d548
pubmed: 21325005
Transl Psychiatry. 2017 Aug 15;7(8):e1208
pubmed: 28809860
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Brain Behav Immun. 2015 Oct;49:206-15
pubmed: 26065825
Int J Geriatr Psychiatry. 2015 Sep;30(9):976-84
pubmed: 25537199
Nat Rev Neurosci. 2015 Jun;16(6):358-72
pubmed: 25991443
J Am Geriatr Soc. 2014 Sep;62(9):1683-91
pubmed: 25123210
J Gerontol A Biol Sci Med Sci. 2004 Mar;59(3):242-8
pubmed: 15031308
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Gerontol A Biol Sci Med Sci. 2009 Apr;64(4):455-61
pubmed: 19196644
Ageing Res Rev. 2016 Nov;31:1-8
pubmed: 27592340
Am J Epidemiol. 2014 Jan 1;179(1):48-56
pubmed: 24064740
Lancet. 2010 Jan 9;375(9709):132-40
pubmed: 20031199
Int J Behav Dev. 2009;33(6):565-576
pubmed: 23885133
Circulation. 2009 Nov 24;120(21):2036-9
pubmed: 19901186
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
J Gerontol A Biol Sci Med Sci. 2000 Dec;55(12):M709-15
pubmed: 11129392
J Gerontol A Biol Sci Med Sci. 2012 Sep;67(9):970-6
pubmed: 22367431
Lancet. 2012 Mar 31;379(9822):1214-24
pubmed: 22421340
Eur J Clin Nutr. 2014 Feb;68(2):155-8
pubmed: 24327120
Int J Geriatr Psychiatry. 2015 Feb;30(2):156-65
pubmed: 25475551
J Gerontol A Biol Sci Med Sci. 2017 Sep 1;72(9):1218-1225
pubmed: 28003373